S
Saegis Pharmaceuticals
Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders
About Saegis Pharmaceuticals
Saegis Pharmaceuticals was a company that focused on developing and commercializing medicines for disorders of the brain and central nervous system. The company's main focus was on neurological conditions that affect memory and cognition.
Read full description
Saegis was building a portfolio of small molecule therapeutic compounds. These were aimed at treating conditions such as Alzheimer's disease, mild cognitive impairment, and adult attention deficit disorder. The company's strategy involved a combination of in-licensing promising compounds and conducting its own research and development to bring these potential therapies to market.
Founded in 1999 and based in California, Saegis Pharmaceuticals operated in the biotechnology and pharmaceutical sector. In November 2008, the company was acquired by Lundbeck, a global pharmaceutical company. This acquisition marked the conclusion of Saegis's operations as an independent entity.
At a glance
- Status
- Operational
- Founded
- 1999
- Headquarters
- Half Moon Bay, United States
- Open positions
- None listed
- Dealroom signal
- 18.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning Saegis Pharmaceuticals.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Nov 2003 | $30M | $120M | Technology Partners · Polaris Partners · Sofinnova Partners · NeuroVentures | — |
| SERIES A✓Equity / VC | Jan 2001 | $14M | $56M | Sofinnova Investments | — |
Growth signals
Latest recorded traffic for Saegis Pharmaceuticals is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Sofinnova Investments
Versant Ventures
Technology Partners
Polaris Partners
Sofinnova Partners
NeuroVentures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Saegis Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Saegis Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.